Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced Gastroesophageal Junction Adenocarcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT04580485
What this trial is testing

INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors

Who this might be right for
Ovarian CancerBladder CancerNon Small Cell Lung Cancer+8 more
Incyte Corporation 54
Testing effectiveness (Phase 2)UnknownNCT05111444
What this trial is testing

Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Who this might be right for
Gastric NeoplasmsGastroesophageal Junction Adenocarcinoma
Fudan University 65
Testing effectiveness (Phase 2)Ended earlyNCT04032704
What this trial is testing

Ladiratuzumab Vedotin in Advanced Solid Tumors

Who this might be right for
Small Cell Lung CancerNon-small Cell Lung Cancer, SquamousNon-small Cell Lung Cancer, Non-squamous+6 more
Seagen Inc. 205
Early research (Phase 1)Study completedNCT03752398
What this trial is testing

XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)

Who this might be right for
Melanoma (Excluding Uveal Melanoma)Cervical CarcinomaPancreatic Carcinoma+13 more
Xencor, Inc. 198
Not applicableLooking for participantsNCT06277024
What this trial is testing

A Study on the Safety and Efficacy of the Combination of Candenizumab, Lenvatinib, and SOX Regimen in the Treatment of HER2 Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Patients

Who this might be right for
Overall Response Rate
Fujian Medical University 50
Testing effectiveness (Phase 2)UnknownNCT04202484
What this trial is testing

Tripletrumab Combined With Oxaliplatin and Teggio (SOX) in First-line Treatment of Gastric and Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric Cancer
RenJi Hospital 20
Testing effectiveness (Phase 2)UnknownNCT06030934
What this trial is testing

Study of The Second-line Treatment of Advanced Gastric / Gastroesophageal Junction Adenocarcinoma With Envafolimab and Lenvatinib Combined With Paclitaxel-albumin

Who this might be right for
Gastric / Gastroesophageal Junction Adenocarcinoma
Fudan University 30
Testing effectiveness (Phase 2)WithdrawnNCT03704077
What this trial is testing

An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric CancerCancer of the StomachStomach Cancer+1 more
Bristol-Myers Squibb
Testing effectiveness (Phase 2)Study completedNCT00217581
What this trial is testing

Bevacizumab, Oxaliplatin, and Docetaxel in Treating Patients With Locally Advanced Unresectable or Metastatic Stomach or Gastroesophageal Junction Cancer

Who this might be right for
Esophageal CancerGastric Cancer
Barbara Ann Karmanos Cancer Institute 39
Testing effectiveness (Phase 2)UnknownNCT03221400
What this trial is testing

PEN-866 in Patients With Advanced Solid Malignancies

Who this might be right for
CarcinomaEndometrial AdenocarcinomaNeoplasms+16 more
Tarveda Therapeutics 340
Large-scale testing (Phase 3)Study completedNCT04375605
What this trial is testing

Neoadjuvant RCT Versus CT for Patients With Locally Advanced, Potentially Resectable Adenocarcinoma of the GEJ

Who this might be right for
Gastroesophageal Junction Adenocarcinoma
Universitätsmedizin Mannheim 342
Testing effectiveness (Phase 2)Looking for participantsNCT07689851
What this trial is testing

Chemoradiotherapy and SHR-1701 in Patients With Unresectable Gastric Cancer

Who this might be right for
Gastric Cancer (GC)Gastroesophageal Junction Adenocarcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 60
Large-scale testing (Phase 3)Not Yet RecruitingNCT06944496
What this trial is testing

Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric Carcinoma
RemeGen Co., Ltd. 616
Large-scale testing (Phase 3)Looking for participantsNCT07043400
What this trial is testing

Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Metastatic Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
BeOne Medicines 351
Large-scale testing (Phase 3)Looking for participantsNCT06649292
What this trial is testing

SHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Shanghai Hengrui Pharmaceutical Co., Ltd. 524
Testing effectiveness (Phase 2)Looking for participantsNCT06445972
What this trial is testing

Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)

Who this might be right for
Gastroesophageal JunctionGastroesophageal AdenocarcinomaEsophageal Neoplasms+1 more
Merck Sharp & Dohme LLC 210
Early research (Phase 1)UnknownNCT03276156
What this trial is testing

Apatinib in Combination With S-1 as Second-Line Treatment in Patients With Advanced Gastric Cancer

Who this might be right for
Gastric Cancer
Zhejiang Cancer Hospital 12
Large-scale testing (Phase 3)Looking for participantsNCT07518147
What this trial is testing

A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment

Who this might be right for
Gastric CancerGastroesophageal Junction Adenocarcinoma
Sichuan Baili Pharmaceutical Co., Ltd. 438
Testing effectiveness (Phase 2)Study completedNCT05394740
What this trial is testing

Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaEsophageal Adenocarcinoma
National Cancer Center Hospital East 30
Early research (Phase 1)Study completedNCT03517488
What this trial is testing

XmAb®20717 in Subjects With Selected Advanced Solid Tumors

Who this might be right for
MelanomaBreast CarcinomaHepatocellular Carcinoma+25 more
Xencor, Inc. 150
Next Page